A Frost & Sullivan Report
Redefining Value in Biologics Outsourcing
Discover the latest trends, challenges, and strategic insights shaping the future of biologics outsourcing partnerships.
Let's get started
The biologics manufacturing landscape has undergone a fundamental transformation over the past decade.
What began as transactional outsourcing relationships has evolved into strategic partnerships defined by innovation, specialized expertise, and shared success. This shift is driven by the increasing complexity of biologics, the emergence of new therapeutic modalities, geopolitical pressures, and supply chain challenges that demand more from manufacturing partners than ever before.
Contract development and manufacturing organizations (CDMOs) have responded by redefining their value proposition, offering integrated, digitally enabled, and flexible services. As highlighted in the latest Syngene and Frost & Sullivan survey of CMC consultants, the industry is moving rapidly toward strategic collaborations that prioritize end-to-end capabilities and innovation. This report explores how these changes are creating both opportunities and challenges, examining the factors that distinguish meaningful partnerships from vendor relationships, and how organizations like Syngene are positioning themselves as partners of choice in this dynamic environment.
What's inside the report
Why biologics outsourcing is now a strategic imperative for pharma and biotech companies
Key drivers of market growth, platform diversification, and evolving regional manufacturing trends
Market growth forecasts and platform trends through 2030
Insights into sponsor priorities and expectations in CDMO partnerships
Analysis of regional dynamics and global supply chain strategies
Criteria for selecting strategic CDMO partners
Future needs: service integration, advanced therapies, and technology innovation
What sponsors value most in CDMO partnerships—capabilities, regulatory excellence, and flexibility
How Syngene differentiates itself with integrated, end-to-end biologics solutions and a global footprint
Get in touch
Other links
© 2025. Syngene International Limited